On Monday, Shares of General Electric Company (NYSE:GE), subtract -0.65% and closed at $30.51 in the last trading session. The last trading range of the stock ranges between $30.49 and $30.85. The company’s Market capitalization is $272.57 Billion with the total Outstanding Shares of 8.85 billion. During the 52-week trading session the minimum price at which share price traded, registered at $27.10 and reached to max level of $33.00. The EPS of company is strolling at 1.02. GE Digital (GE) recently declared it has attained ServiceMax, a leader in cloud-based field service administration (FSM) solutions, for $915 million. The acquisition provides GE Digital with improved capabilities to advance its Industrial Internet vision, enabling customers to right away gain more value from their assets and find greater efficiency in their field service processes.
Service has always been a core part of GE’s strategy and capability and was an early target for the company’s work in analytics and productivity. GE has invested in the build out of digital twins for industrial assets. In addition the company has accelerated productivity improvements through digitizing service processes. The ServiceMax product offering was an essential element to driving GE internal productivity. With this acquisition GE plans to add analytics and insights into the ServiceMax logistics, workforce optimization and deployment models. GE estimates there is a market-wide opportunity to improve service productivity by $25 billion through the use of analytical tools.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), dropped -2.50% and closed at $17.55 in the last trading session. The last trading range of the stock ranges between $17.26 and $18.71. The company’s Market capitalization is $6.42 Billion with the total Outstanding Shares of 341.19 million. During the 52-week trading session the minimum price at which share price traded, registered at $13.77 and reached to max level of $119.87. The EPS of company is strolling at -6.48. Pharming Group N.V. (the “Company”) (PHARM.AS) recently declared that the results of its “Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human C1 Inhibitor for Prophylaxis of Hereditary Angioedema Attacks”, were presented by Marco Cicardi, Professor of Internal Medicine University of Milan, Hospital L. Sacco Milan and co-prinicipal investigator for the study. The presentation was held during the American College of Allergy, Asthma and Immunology 2016 Scientific Meeting (“ACAAI”) meeting in San Francisco yesterday afternoon. The presentation can be found on our website.